SHANGHAI—Allist Pharmaceuticals Co., Ltd, a Shanghai-based biotech company, has entered into a licensing agreement with fellow Chinese firm Jacobio Pharma (HKG: 1167), securing rights to Jacobio’s KRAS G12C inhibitor glecirasib and SHP2 inhibitor JAB-3312 for research, development, manufacturing, regulatory filings, and commercialization in Greater China. The agreement encompasses mainland China, Hong Kong, Macau, and Taiwan.
Under the terms of the deal, Allist will make an upfront payment of RMB 150 million (USD 21.1 million) to Jacobio and is committed to potential milestone payments of up to RMB 700 million (USD 98.7 million), along with double-digit royalties on sales. This strategic partnership highlights the growing interest in targeted therapies for oncology and the potential of these inhibitors in treating advanced solid tumors.
Glecirasib, developed by Jacobio, is currently under clinical investigation in China, the United States, and Europe for patients with advanced solid tumors that harbor the KRAS G12C mutation. The drug is being evaluated in combination with JAB-3312 in non-small cell lung cancer (NSCLC) and with cetuximab in colorectal cancer. Its potential in pancreatic cancer has been recognized with orphan drug designation in the United States and breakthrough therapy designation in China.
JAB-3312, a highly selective SHP2 allosteric inhibitor, is also being evaluated in clinical trials for monotherapy and in combination with glecirasib and other agents. The Phase III study combining JAB-3312 with glecirasib in first-line KRAS G12C mutant NSCLC has already begun, indicating the momentum behind these promising therapies.
This licensing agreement not only strengthens Allist’s pipeline but also underscores the importance of strategic partnerships in advancing novel cancer treatments. It positions Allist to potentially bring these innovative therapies to patients in Greater China, subject to successful clinical outcomes and regulatory approvals. – Flcube.com
